374 related articles for article (PubMed ID: 22140506)
1. CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer.
Chen YS; Wu MJ; Huang CY; Lin SC; Chuang TH; Yu CC; Lo JF
PLoS One; 2011; 6(11):e28053. PubMed ID: 22140506
[TBL] [Abstract][Full Text] [Related]
2. Elimination of head and neck cancer initiating cells through targeting glucose regulated protein78 signaling.
Wu MJ; Jan CI; Tsay YG; Yu YH; Huang CY; Lin SC; Liu CJ; Chen YS; Lo JF; Yu CC
Mol Cancer; 2010 Oct; 9():283. PubMed ID: 20979610
[TBL] [Abstract][Full Text] [Related]
3. The epithelial-mesenchymal transition mediator S100A4 maintains cancer-initiating cells in head and neck cancers.
Lo JF; Yu CC; Chiou SH; Huang CY; Jan CI; Lin SC; Liu CJ; Hu WY; Yu YH
Cancer Res; 2011 Mar; 71(5):1912-23. PubMed ID: 21169409
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of cancer-initiating cells stemness properties by abrogating S100A4 calcium binding ability in head and neck cancers.
Cheng LH; Hung KF; Huang TF; Hsieh HP; Wang SY; Huang CY; Lo JF
Oncotarget; 2016 Nov; 7(48):78946-78957. PubMed ID: 27793047
[TBL] [Abstract][Full Text] [Related]
5. Targeting cancer initiating cells by promoting cell differentiation and restoring chemosensitivity via dual inactivation of STAT3 and src activity using an active component of antrodia cinnamomea mycelia.
Chang CW; Chen YS; Chen CC; Chan IO; Chen CC; Sheu SJ; Lin TW; Chou SH; Liu CJ; Lee TC; Lo JF
Oncotarget; 2016 Nov; 7(45):73016-73031. PubMed ID: 27682875
[TBL] [Abstract][Full Text] [Related]
6. Sphere culture of murine lung cancer cell lines are enriched with cancer initiating cells.
Morrison BJ; Steel JC; Morris JC
PLoS One; 2012; 7(11):e49752. PubMed ID: 23152931
[TBL] [Abstract][Full Text] [Related]
7. Slug is a novel molecular target for head and neck squamous cell carcinoma stem-like cells.
Moon JH; Lee SH; Koo BS; Kim JM; Huang S; Cho JH; Eun YG; Shin HA; Lim YC
Oral Oncol; 2020 Dec; 111():104948. PubMed ID: 32771963
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer.
Chu PY; Hu FW; Yu CC; Tsai LL; Yu CH; Wu BC; Chen YW; Huang PI; Lo WL
Oral Oncol; 2013 Jan; 49(1):34-41. PubMed ID: 22892238
[TBL] [Abstract][Full Text] [Related]
9. Activation of microRNA-494-targeting Bmi1 and ADAM10 by silibinin ablates cancer stemness and predicts favourable prognostic value in head and neck squamous cell carcinomas.
Chang YC; Jan CI; Peng CY; Lai YC; Hu FW; Yu CC
Oncotarget; 2015 Sep; 6(27):24002-16. PubMed ID: 26090866
[TBL] [Abstract][Full Text] [Related]
10. The biology of head and neck cancer stem cells.
Zhang Z; Filho MS; Nör JE
Oral Oncol; 2012 Jan; 48(1):1-9. PubMed ID: 22070916
[TBL] [Abstract][Full Text] [Related]
11. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells.
Zhang Q; Thomas SM; Xi S; Smithgall TE; Siegfried JM; Kamens J; Gooding WE; Grandis JR
Cancer Res; 2004 Sep; 64(17):6166-73. PubMed ID: 15342401
[TBL] [Abstract][Full Text] [Related]
12. CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis.
Ding Q; Miyazaki Y; Tsukasa K; Matsubara S; Yoshimitsu M; Takao S
Mol Cancer; 2014 Jan; 13():15. PubMed ID: 24468059
[TBL] [Abstract][Full Text] [Related]
13. CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma.
Lai YJ; Yu WN; Kuo SC; Ho CT; Hung CM; Way TD; Chen CT
J Cell Physiol; 2019 Jun; 234(6):9118-9129. PubMed ID: 30341909
[TBL] [Abstract][Full Text] [Related]
14. SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma.
Lee SH; Oh SY; Do SI; Lee HJ; Kang HJ; Rho YS; Bae WJ; Lim YC
Br J Cancer; 2014 Nov; 111(11):2122-30. PubMed ID: 25321191
[TBL] [Abstract][Full Text] [Related]
15. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells.
Tseng LM; Huang PI; Chen YR; Chen YC; Chou YC; Chen YW; Chang YL; Hsu HS; Lan YT; Chen KH; Chi CW; Chiou SH; Yang DM; Lee CH
J Pharmacol Exp Ther; 2012 May; 341(2):410-23. PubMed ID: 22328572
[TBL] [Abstract][Full Text] [Related]
16. Comparative secretome analysis of epithelial and mesenchymal subpopulations of head and neck squamous cell carcinoma identifies S100A4 as a potential therapeutic target.
Rasanen K; Sriswasdi S; Valiga A; Tang HY; Zhang G; Perego M; Somasundaram R; Li L; Speicher K; Klein-Szanto AJ; Basu D; Rustgi AK; Speicher DW; Herlyn M
Mol Cell Proteomics; 2013 Dec; 12(12):3778-92. PubMed ID: 24037664
[TBL] [Abstract][Full Text] [Related]
17. 8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin.
Quan MF; Xiao LH; Liu ZH; Guo H; Ren KQ; Liu F; Cao JG; Deng XY
World J Gastroenterol; 2013; 19(43):7680-95. PubMed ID: 24431896
[TBL] [Abstract][Full Text] [Related]
18. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients.
Zhang SS; Han ZP; Jing YY; Tao SF; Li TJ; Wang H; Wang Y; Li R; Yang Y; Zhao X; Xu XD; Yu ED; Rui YC; Liu HJ; Zhang L; Wei LX
BMC Med; 2012 Aug; 10():85. PubMed ID: 22871210
[TBL] [Abstract][Full Text] [Related]
19. Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties.
Su YJ; Lin WH; Chang YW; Wei KC; Liang CL; Chen SC; Lee JL
Oncotarget; 2015 Nov; 6(35):38029-45. PubMed ID: 26515729
[TBL] [Abstract][Full Text] [Related]
20. Conversion to stem-cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells.
Andriani F; Bertolini G; Facchinetti F; Baldoli E; Moro M; Casalini P; Caserini R; Milione M; Leone G; Pelosi G; Pastorino U; Sozzi G; Roz L
Mol Oncol; 2016 Feb; 10(2):253-71. PubMed ID: 26514616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
